Breast Cancer Diagnostics Market Exhaustive Forecast Study Highlights Growth In CAGR Of 4.7% And US$ 2,000 Mn In Revenues By 2022-End

The global market for breast cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of breast cancer patients.

Key players in the Global Breast Cancer Diagnostics Market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on breast cancer patients. Such cooperative efforts are of paramount importance in the global breast cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Request a Free Sample Report Here –

Breast cancer is a cancer that develops when cells and tissues in the breast begin to grow out of control. Usually forming into a tumor, breast cancer is visible as a lump surrounding the internal breast tissues. Breast cancer tumor is malignant, and occurs almost entirely in women, apart from exceptional occurrences in men.

Breast cancer has become the most common type of cancer for women across the globe. The number of women suffering from breast cancer is witnessing a surge. This has led towards necessity for efficient early detection of breast cancer. Mammography screening, an established method adopted across several countries, has been recently been observed to offer inconclusive test results. Risk-adapted, personalized therapy and screening are predicted to resolve these difficulties. In addition, tomosynthesis, a new imaging technology, has been seen to overcome the drawbacks of mammography.

Screening options for breast cancer have been witnessing a rise, and have been altering practices of early detection across industrialized economies. Moreover, countries such as Brazil, India and China are focusing on development of cost-effective screening strategies capable of being adapted as per requirements.

The global breast cancer diagnostics market has been witnessing a robust transformation on the back of several technological advancements in the diagnostic platforms. The market has witnessed the introduction of hybrid imaging instruments which offer an enhanced accuracy. These advancements have been augmenting growth of the global breast cancer diagnostics market. Increasing incidences of breast cancer and growth in older female population are expected to create lucrative growth opportunities for breast cancer diagnostics. In contrast, shortage of skilled and trained personnel is expected to pose a major challenge to the market growth of breast cancer diagnostics.

View Full Report Here –

By test type, BRCA is expected to remain dominant in the market, with sales poised to surpass US$ 500 Mn by 2022-end. CA test for breast cancer are expected to exhibit the highest CAGR in the market through 2022, followed by ER & PR test. However, revenue from CA, and ER & PR tests will remain low during the forecast period. HER 2 test will remain the second largest test type segment in the global breast cancer diagnostics market. Revenue from EGFR mutation test will continue to be low in the global breast cancer diagnostics market.

Hospital-associated Labs to Remain the Largest End-Users in Breast Cancer Diagnostics Market

Hospital-associated labs are expected to remain the largest end-users of breast cancer diagnostics in the global market. Breast cancer diagnostics in hospital-associated labs will account for the largest revenues by 2022-end, followed by independent diagnostic laboratories. Cancer research institutes are expected to register the highest CAGR through 2022.

Competition Tracking

Key market players mentioned in Fact.MR’s report include Abbott Laboratories, Roche Holding AG, Thermo Fischer Scientific, Inc., Siemens AG, Bio-Rad Laboratories, Inc., Illumina, Inc., Biocept, Inc., Epigenomics AG, AstraZeneca plc, Myriad Genetics, Inc., and Quest Diagnostics Incorporated.

Table of Contents

Chapter 1 Global Breast Cancer Diagnostics Market – Executive Summary 19

Chapter 2 Global Breast Cancer Diagnostics Market Overview 21

2.1 Introduction 21

2.1.1 Global Breast Cancer Diagnostics Market Taxonomy 21

2.1.2 Global Breast Cancer Diagnostics Market Definition 21

2.2 Global Breast Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022 22

2.2.1 Global Breast Cancer Diagnostics Market Y-o-Y Growth 22

2.3 Global Breast Cancer Diagnostics Market Dynamics 22

2.3.1 Drivers 22

2.3.2 Restraints 22

2.3.3 Trends 23

2.4 Supply Chain 23

2.5 Epidemiology 23

2.6 List of Distributors 23

2.7 Average Pricing Analysis 23

2.8 Regulations 24 ……………………………Continued

If You Need This Useful Report Then Buy This Report Here –

About FactMR

FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized Sports market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that’s why we publish multi-industry global, regional, and country-specific research reports.

Contact Us –

Suite 9884
27 Upper Pembroke Street, Dublin 2, Ireland
Telephone @ +353-1-6111-593

Matched content

Editor’s pick

Express Press Release Distribution